Ainos, Inc.
Close on Oct 19, 2026
- Market cap
- $6.85M
- P/E (TTM)
- –
- Dividend yield
- –
About Ainos
Computer Peripheral Equipment, NEC, SIC 3577
Ainos, Inc. is a technology and healthcare company that specializes in artificial intelligence-powered scent digitization and immune therapeutics. Its flagship technology, AI Nose, utilizes gas sensor arrays and a proprietary smell language model to convert scent and volatile organic compound signals into digital data for real-time detection, analysis, and environmental monitoring. Initially created for healthcare use cases such as point-of-care testing and infection monitoring, the platform also targets industrial applications, including semiconductor manufacturing, robotics, and smart production facilities. The company operates a subsidiary, ScentAI Inc., dedicated to algorithm development, and additionally develops low-dose oral interferon therapies under its VELDONA platform for rare, autoimmune, and infectious diseases, alongside commercial pet supplements.
The company is based in Houston, Texas, and conducts its research and development and operational activities primarily in Taiwan. Ainos relies on third-party manufacturing partners for its hardware, testing candidates, and therapeutic formulations, while maintaining commercial relationships across various international technology and biotech firms.
Summary of the business section of Ainos's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Ainos, Inc.
- Founded
- 1984
- Headquarters
- Houston, TX
- Address
- 3050 Post Oak Blvd,, Suite 510-T80 77056
- Phone
- (281) 898-6586
- Website
- ainos.com
- Employees
- 41, Dec 31, 2025
- Industry
- Computer Peripheral Equipment, NEC
- Incorporated in
- Texas
- Fiscal year ends
- December 31
- Auditor
- KCCW Accountancy Corp, Diamond Bar, California
Stock & identifiers
- Ticker
- AIMD
- Other tickers
- AIMDW
- Exchange
- Nasdaq
- Shares outstanding
- 7M, Aug 3, 2026
- Public float
- $4.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-5 reverse, Aug 13, 2025; 1-for-5 reverse, Jun 30, 2025; 1-for-5 reverse, Mar 8, 2024; 1-for-5 reverse, Dec 14, 2023; 1-for-15 reverse, Aug 9, 2022
- SEC CIK
- 1014763
- CUSIP
- 00902F402
- ISIN
- US00902F4028
- LEI
- 549300AX97HS3UDQ2Y10
- EIN
- 75-1974352
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| chun-hsien tsai | CEO, PRESIDENT, CHAIRMAN, Director | 710,372 |
| Hsin-Liang Christopher Lee | CFO | 75,275 |
| yao-chung chiang | Director | 102,559 |
| Chun-Jung Tsai | Director | 658,199 |
| ting-chuan lee | Director | 807,417 |
| chung-yi tsai | Director | 90,880 |
| wen-han chang | Director | 4,101,546 |
| Pao-Sheng Wei | Director | 90,880 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Chun Hsien Tsai | $301.52K | $20.67K | $216.10K | $-96 | – |
| FY2023 Chun Hsien Tsai | $1.29M | $987.42K | $482.13K | $-84 | – |
| FY2022 Chun Hsien Tsai | $3.82M | $777.96K | $1.70M | $-76 | – |
| FY2021 Chun Hsien Tsai | $63.06K | $63.06K | $603.45K | $394 | – |
| FY2021 Stephen TChen | $34.31K | $34.31K | $603.45K | $394 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of December 31, 2025, we had 41 full-time employees, of whom 20 were engaged in research and development.”
Corporate history
Events identified from SEC filings